Salmonella Typhi Outer Membrane Protein (OMP), His-Tag (E. coli)

(No reviews yet) Write a Review
SKU:
LGC-REC31853
£906.05

 Select your currency from the header

Description

SALMONELLA TYPHI OUTER MEMBRANE PROTEIN (OMP)

Salmonella typhi Outer Membrane Protein (OMP) is a recombinant antigen manufactured in E. coli cells for immunoassay development and other applications.

 

PRODUCT DETAILS – SALMONELLA TYPHI HEMOLYSIN E PROTEIN

  • Recombinant Salmonella typhi Outer Membrane Protein (OMP)
  • Approximately 52 kDa protein, expressed and purified from E. coli with His-tag
  • Greater than 95% purity
  • Presented lyophilized, buffer contains 20mM Na-carbonate Buffer, pH10
  • Suitable for use in ELISA and Western Blot

 

BACKGROUND

Typhoid fever is an acute systemic illness caused by Salmonella enterica serovar Typhi which leads to infections in children and adults resulting in high morbidity (Paul & Bandyopadhyay, 2017). S. enterica are noncapsulated, nonsporulating, facultative anaerobic bacilli, which contain in their outer membrane a group of proteins (OMPs) which include Braun’s lipoprotein, the porins (ompC, ompF, ompD, phoE, etc.) and the heat-modifiable protein (Omp A). The cell outer membrane proteins (OMPs) play an essential role in adaptation to environmental conditions, motility, adherence, and host cell colonization. These proteins also function in the transmembrane transport of nutrients and ions and play a significant role in the injection of toxins and cellular proteases, as well as the formation of channels for the removal of antibiotics (efflux pumps).

Vaccination against S. typhi is an essential tool for the effective management of typhoid fever. However, the currently available typhoid vaccines have several limitations such as short-term immunity, and they are not cost effective. S. typhi OMPs have been demonstrated to be potent immunogens, which elicit long-lasting and protective immunity (Liu et al., 2016) and several have been investigated as potential vaccine candidates, virulence factors, and diagnostic antigens (Isibasi et al., 1988). For example, the OMP from S. typhi is a major immunogenic target to synovial fluid lymphocytes of patients with reactive arthritis (ReA)/undifferentiated spondyloarthropathy (uSpA) (Pocanschi et al. 2013). Therefore, these antigens are useful candidates for vaccine studies.

 

REFERENCES

  • Isibasi, A., V. Ortiz, M. Vargas, J. Paniagua, C. Gonzalez, J. Moreno, and J. Kumate. 1988. Protection against Salmonella typhi infection in mice after immunization with outer membrane proteins isolated from Salmonella typhi 9,12,d,Vi. Infect. Immun.56:2953-2959.
  • Liu Q, Liu Q, Yi J, et al. Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model. Int J Med Microbiol. 2016;306(8):697‐706.
  • Paul UK, Bandyopadhyay A. Typhoid fever: A review. International Journal of Advanced Medicine. 2017;4(2):300–306.
  • Pocanschi CL, Popot JL, Kleinschmidt JH. Folding and stability of outer membrane protein A (OmpA) from Escherichia coli in an amphipathic polymer, amphipol A8-35. Eur Biophys J. 2013;42(2-3):103‐118.
View AllClose

0 Reviews

View AllClose